Clinical Trials

Inclusion Criteria:

• Age ≤ 30 years.
• Histological confirmation of neuroblastoma, ganglioneuroblastoma, or ganglioneuroma.
• High-risk neuroblastoma requiring consolidative RT, as determined by the treating radiation oncologist.
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3 (patients 16 y.o. or older at entry) or Lansky Score of 30-100 (patients < 16 y.o. at entry).
• Planned for radiation planning and RT at enrolling institution.
• Documented negative pregnancy test prior to induction chemotherapy, for women of childbearing age within ≤ 7 days prior to registration.
• Signed written informed consent from patient, parent, and/or legal guardian.
• Willing to return to enrolling institution for follow-up imaging and clinical evaluation, or willing to send follow-up imaging and clinical notes to enrolling institution (during the Observation Phase of the study).

Exclusion Criteria:

• Pregnant women, nursing women who refuse to stop breastfeeding, or men/women of childbearing age who are unwilling to use an effective birth control method.
• Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
• Immunocompromised patients and patients known to be human immunodeficiency virus positive and currently receiving antiretroviral therapy.  
  • NOTE:  Patients known to be human immunodeficiency virus positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/25/24. Questions regarding updates should be directed to the study team contact.